Drug-induced liver injury: a summary of recent advances
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: The knowledge base of drug-induced liver injury (DILI) continues to grow each year as additional drugs are identified as hepatotoxins. There is still a need to improve our ability to predict and diagnose DILI in the preclinical and post-approval settings. AREAS COVERED: This article presents the new and updated DILI registries for 2010, including the latest information on the causes and outcomes of non-acetaminophen DILI cases in the US Acute Liver Failure Study Group database. As DILI is still largely a diagnosis of exclusion, it is appropriate that causality assessment instruments are again the subject of considerable discussion. EXPERT OPINION: DILI research remains extremely active including studies aimed at being better able to identify causative agents, utilize potential biomarkers, predict who is at greatest risk of injury and manage outcomes. With respect to identifying DILI risk factors at the genetic level, the field is rapidly approaching the day where 'personalized medicine' (based on pharmacogenomics) will become a reality. A large single-center series from India reminds us that geography can influence the drugs responsible for liver injury; however, Hy's law remains universal. As our DILI knowledge continues to grow, it remains essential to keep abreast of the important changes reported each year.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pharmaco-metabonomic phenotyping and personalized drug treatment
Andrew Clayton, T., Lindon, J. C., Cloarec, O., Antti, H., Charuel, C., Hanton, G., Provost, J.-P., Le Net, J.-L., Baker, D., Walley, R. J., et al. (2006) · Nature · doi:10.1038/nature04648 · Cited by 824 · cited 1×
“Research into the fields of proteomics, metabolomics, transcriptomics and pharmacogenomics (providing for a personalized medicine approach) is being increasingly directed to find clues in the accurate prediction of DILI [25,26].”
BackgroundDrug-Induced Acute Liver Failure: Results of a U.S. Multicenter, Prospective Study
Reuben, A., Koch, D. G., & Lee, W. M. (2010) · Hepatology · doi:10.1002/hep.23937 · Cited by 772
Risk Factors for Idiosyncratic Drug-Induced Liver Injury
Chalasani, N., & Björnsson, E. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.04.001 · Cited by 347 · cited 2×
“Drugs that are metabolized via CYP 2C9 and 2C19 were associated with a greater risk of DILI, while those metabolized via 3A and 2D6 were less likely to be associated with DILI [15,18].”
BackgroundDissimilar Hepatotoxicity Profiles of Propylthiouracil and Methimazole in Children
Rivkees, S. A., & Szarfman, A. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2546 · Cited by 177 · cited 1×
“5 Propylthiouracil PTU-associated liver injury appears to selectively target younger patients [87-89], especially African-American females.”
BackgroundHow safe is the use of thiazolidinediones in clinical practice?
Rizos, C., Elisaf, M., Mikhailidis, D., & Liberopoulos, E. (2009) · Expert Opinion on Drug Safety · doi:10.1517/14740330802597821 · Cited by 161
Nguyen, G. C., Sam, J., & Thuluvath, P. J. (2008) · Hepatology · doi:10.1002/hep.22536 · Cited by 107 · cited 1×
“[56] and confirmed by Myers and Shaheen [57] that virus infection, including hepatitis C, is a risk factor for hepatotoxicity.”
BackgroundPropylthiouracil (PTU) Hepatoxicity in Children and Recommendations for Discontinuation of Use
Rivkees, S., & Mattison, D. (2009) · International Journal of Pediatric Endocrinology · doi:10.1186/1687-9856-2009-132041 · Cited by 90
Sivilotti, M. L. A., Green, T. J., Langmann, C., Yarema, M., Juurlink, D., & Johnson, D. (2010) · Clinical Toxicology · doi:10.3109/15563650.2010.523829 · Cited by 56 · cited 2×
“If validated, this predictor might reduce or eliminate the need to identify the time of ingestion among overdose victims, which is often fraught with error [61].”
BackgroundAntibiotic-Induced Liver Toxicity: Mechanisms, Clinical Features and Causality Assessment
Robles, M., Toscano, E., Cotta, J., Isabel Lucena, M., & J. Andrade, R. (2010) · Current Drug Safety · doi:10.2174/157488610791698307 · Cited by 45
Myers, R. P., & Shaheen, A. A. M. (2009) · Hepatology · doi:10.1002/hep.22798 · Cited by 36 · cited 2×
“[56] and confirmed by Myers and Shaheen [57] that virus infection, including hepatitis C, is a risk factor for hepatotoxicity.”
Background
Cited by
Multi-cell type human liver microtissues for hepatotoxicity testing
Messner, S., Agarkova, I., Moritz, W., & Kelm, J. M. (2013) · Archives of Toxicology · doi:10.1007/s00204-012-0968-2 · Cited by 319
CSH guidelines for the diagnosis and treatment of drug-induced liver injury
Drug-induced Liver Injury (DILI) Study Group, Yu, Y.-C., Chinese Society of Hepatology (CSH), Chinese Medical Association (CMA), Mao, Y.-M., Chen, C.-W., Chen, J.-J., Chen, J., Cong, W.-M., Ding, Y., et al. (2017) · Hepatology International · doi:10.1007/s12072-017-9793-2 · Cited by 254
Morgan, R. E., van Staden, C. J., Chen, Y., Kalyanaraman, N., Kalanzi, J., Dunn, R. T., Afshari, C. A., & Hamadeh, H. K. (2013) · Toxicological Sciences · doi:10.1093/toxsci/kft176 · Cited by 243
Metadata
- Authors
- Stine, J. G., & Lewis, J. H.
- Venue
- Expert Opinion on Drug Metabolism & Toxicology
- Publisher
- Informa UK Limited
- Published
- 2011-04-21
- Volume
- 7
- Issue
- 7
- Pages
- 875-890
- ISSN
- 1742-5255 (ISSN-L)
- 1744-7607
- OpenAlex
- W2163059491
- Cited by
- 53
- References
- 10
- FWCI
- 9.59
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Drug-induced liver injury: a summary of recent advances. https://app.cochat.ai/papers/10.1517/17425255.2011.577415
- The paper
- Stine, J. G., & Lewis, J. H. (2011). Drug-induced liver injury: a summary of recent advances. Expert Opinion on Drug Metabolism & Toxicology. https://doi.org/10.1517/17425255.2011.577415
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.